ALB vs AMPX: How Albemarle and Amprius Technologies Compare (2026)

Same yardstick, side by side (as of July 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

Reading it: ALB is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. ALB and AMPX share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined ALB and AMPX exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Albemarle (ALB) is one of the world's largest producers of lithium, a critical input for the batteries that power electric vehicles, consumer electronics, and grid storage. Its Energy Storage segment mines and processes lithium from hard-rock and brine resources into battery-grade lithium hydroxide and carbonate sold to battery makers and automakers. Albemarle also runs a Specialties business (bromine-based flame retardants and other fine chemicals used in electronics, construction, and oilfield applications) and a catalysts business serving refining and petrochemical customers. The lithium segment drives most of the company's growth narrative and its share-price volatility, because lithium prices swing sharply with the supply-demand balance of the EV battery supply chain. Albemarle controls some of the lowest-cost and largest lithium resources in the world, including assets in Chile, Australia, and the United States. Founded in 1994 and headquartered in Charlotte, North Carolina, Albemarle is a cyclical specialty-chemicals company whose fortunes are tightly linked to electric vehicle adoption and lithium pricing.

Full ALB guide

Amprius Technologies develops and sells silicon-anode lithium-ion batteries that target higher energy density than conventional graphite-anode cells, meaning more energy in the same weight and volume. Its SiMaxx platform uses a proprietary 100% silicon-nanowire anode made in-house at its Fremont, California facility and is positioned for the most demanding high-performance uses, while its newer SiCore platform is a commercially available silicon-anode line, including a 450 Wh/kg cell, designed for near-term mass production. Higher energy density matters most where weight is critical, which is why Amprius concentrates on aviation, electric vertical takeoff and landing (eVTOL) aircraft, drones, defense, and electric vehicles. The company ships cells to a broad and growing base of customers and holds defense agreements such as a contract with the U.S. Defense Innovation Unit for NDAA-compliant advanced drone batteries.

Full AMPX guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• ALB drivers: Lithium and EV demand; Low-cost resource position.
• AMPX drivers: Energy-density edge; Aviation, defense, and drone demand.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: Albemarle's earnings are extremely sensitive to lithium prices, which collapsed from their 2022 peak as supply caught up with demand and EV growth cooled, swinging the company from large profits toward losses. For AMPX, amprius is in an early commercial ramp and is not yet consistently profitable, so it depends on its cash balance and may need to raise capital, which can dilute shareholders.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick ALB if you believe its drivers more; AMPX if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the ALB and AMPX guides.

ALB. Albemarle is a commodity-linked specialty chemicals company, so traditional P/E framing is unreliable: earnings swing from large profits at peak lithium prices to losses in troughs. The market values it on the long-term lithium demand story and its low-cost resource base, with the share price highly sensitive to lithium spot prices and EV adoption sentiment rather than steady-state multiples.

AMPX. Amprius is a speculative, ramp-stage company, so it cannot be valued on current earnings; the market prices it largely on the option value of future growth and scale. Figures are approximate and change frequently, especially cash, share count, and market cap, which capital raises and dilution can move materially. Verify the latest filings before relying on any number.

Headline figures (approximate, early 2026): ALB shows revenue (ttm) ~$5 billion (down sharply from the lithium-price peak), operating margin Volatile; thin or negative in lithium-price troughs, earnings Swings between profit and loss with lithium prices, dividend yield ~2-3%; AMPX shows revenue (fy2025) ~$73.0 million (up over 3x year over year), revenue (q1 2026) ~$28.5 million (up ~153% year over year), net loss (fy2025) ~$44.0 million (incl. ~$22.5M Colorado impairment; ~$21.5M adjusted), cash and equivalents ~$91.9 million reported at end of 2025 (verify latest).

ALB and AMPX are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined ALB and AMPX exposure against your real portfolio. It is not an investment adviser.